Author details
1 1Shandong Provincial Medicine and Health Key Laboratory of Clinical
Anesthesia, School of Anesthesiology, Weifang Medical University, No. 7166,
Baotong West Street, Weicheng District, Weifang 261021, China. 2Department
of Pain, Affiliated Hospital of Weifang Medical University, Weifang 261000,
China. Open Access Correction to: Dexmedetomidine
attenuates myocardial ischemia-reperfusion
injury in vitro by inhibiting NLRP3
Inflammasome activation Yaru Huang1†, Xiaotong Sun1†, Zhaodong Juan1*, Rui Zhang1, Ruoguo Wang2, Shuqi Meng1, Jiajia Zhou1, Yan Li1,
Keyou Xu1 and Keliang Xie1* Correction to: BMC Anesthesiol 21, 104 (2021)
https://doi.org/10.1186/s12871-021-01334-5 Correction to: BMC Anesthesiol 21, 104 (2021)
https://doi.org/10.1186/s12871-021-01334-5 In the article “Dexmedetomidine attenuates myocar-
dial ischemia-reperfusion injury in vitro by inhibiting
NLRP3 Inflammasome activation. BMC ANESTHESIOL
2021, 21(1):104” [1] 1uM MCC950 is corrected to 1 μM
MCC950 in the Fig. 1a on page 3 of 12. The original article can be found online at https://doi.org/10.1186/s12871-
021-01334-5. * Correspondence: juanzd@wfmc.edu.cn; xiekeliang2009@hotmail.com
†Yaru Huang and Xiaotong Sun contributed equally to this work. 1Shandong Provincial Medicine and Health Key Laboratory of Clinical
Anesthesia, School of Anesthesiology, Weifang Medical University, No. 7166,
Baotong West Street, Weicheng District, Weifang 261021, China
Full list of author information is available at the end of the article © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data. Reference 1. Huang Y, Sun X, Juan Z, Zhang R, Wang R, Meng S, et al. Dexmedetomidine
attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting
NLRP3 Inflammasome activation. BMC Anesthesiol. 2021;21:104. https://doi. org/10.1186/s12871-021-01334-5. The original article can be found online at https://doi.org/10.1186/s12871-
021-01334-5. Huang et al. BMC Anesthesiology          (2021) 21:141 
https://doi.org/10.1186/s12871-021-01356-z Huang et al. BMC Anesthesiology          (2021) 21:141 
https://doi.org/10.1186/s12871-021-01356-z © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data. Page 2 of 2 Huang et al. BMC Anesthesiology          (2021) 21:141 Fig. 1 Experimental protocol and four time points for detecting the beating rate of cardiomyocytes (CMs). a Experimental protocols. Cardiac
fibroblasts (CFs), cardiomyocytes (CMs) and cocultured CMs and CFs (CMs + CFs) were randomly assigned to one of five groups: 1) C group, in
which the cells were incubated under normal conditions in a CO2 incubator; 2) M group, in which the cells were exposed to hypoxia/
reoxygenation as we described above; 3) D group, in which the cells were pretreated with 1 μg/ml dexmedetomidine (DEX) 2 h before hypoxia/
reoxygenation; 4) 950 group, in which the cells were treated with 1 μM MCC950 during hypoxia/reoxygenation and 2 h before it; and 5) D + 950
group, in which the cells were treated with 1 μM MCC950 during DEX preconditioning and hypoxia/reoxygenation,. b Four time points for
detecting the myocardial cell beat frequency of cocultured CMs and CFs (CMs + CFs). We detected the beat frequency of CMs at these four time
points as indicated by the arrow. 1–2 (group M): 1, normal; 2, after hypoxia/reoxygenation. 3–4 (group D): 3, normal; 4, after hypoxia/
reoxygenation. DEX, dexmedetomidine; CMs, cardiomyocytes; CFs, cardiac fibroblasts; CMs + CFs, cocultured cardiomyocytes and cardiac
fibroblasts; MCC950, a potent selective NLRP3 inhibitor     Fig. 1 Experimental protocol and four time points for detecting the beating rate of cardiomyocytes (CMs). a Experimental protocols. Cardiac
fibroblasts (CFs), cardiomyocytes (CMs) and cocultured CMs and CFs (CMs + CFs) were randomly assigned to one of five groups: 1) C group, in
which the cells were incubated under normal conditions in a CO2 incubator; 2) M group, in which the cells were exposed to hypoxia/
reoxygenation as we described above; 3) D group, in which the cells were pretreated with 1 μg/ml dexmedetomidine (DEX) 2 h before hypoxia/
reoxygenation; 4) 950 group, in which the cells were treated with 1 μM MCC950 during hypoxia/reoxygenation and 2 h before it; and 5) D + 950
group, in which the cells were treated with 1 μM MCC950 during DEX preconditioning and hypoxia/reoxygenation,. b Four time points for
detecting the myocardial cell beat frequency of cocultured CMs and CFs (CMs + CFs). We detected the beat frequency of CMs at these four time
points as indicated by the arrow. 1–2 (group M): 1, normal; 2, after hypoxia/reoxygenation. 3–4 (group D): 3, normal; 4, after hypoxia/
reoxygenation. DEX, dexmedetomidine; CMs, cardiomyocytes; CFs, cardiac fibroblasts; CMs + CFs, cocultured cardiomyocytes and cardiac
fibroblasts; MCC950, a potent selective NLRP3 inhibitor Fig. 1 Experimental protocol and four time points for detecting the beating rate of cardiomyocytes (CMs). a Experimental protocols. Cardiac
fibroblasts (CFs), cardiomyocytes (CMs) and cocultured CMs and CFs (CMs + CFs) were randomly assigned to one of five groups: 1) C group, in
which the cells were incubated under normal conditions in a CO2 incubator; 2) M group, in which the cells were exposed to hypoxia/
reoxygenation as we described above; 3) D group, in which the cells were pretreated with 1 μg/ml dexmedetomidine (DEX) 2 h before hypoxia/
reoxygenation; 4) 950 group, in which the cells were treated with 1 μM MCC950 during hypoxia/reoxygenation and 2 h before it; and 5) D + 950
group, in which the cells were treated with 1 μM MCC950 during DEX preconditioning and hypoxia/reoxygenation,. b Four time points for
detecting the myocardial cell beat frequency of cocultured CMs and CFs (CMs + CFs). We detected the beat frequency of CMs at these four time
points as indicated by the arrow. 1–2 (group M): 1, normal; 2, after hypoxia/reoxygenation. 3–4 (group D): 3, normal; 4, after hypoxia/
reoxygenation. DEX, dexmedetomidine; CMs, cardiomyocytes; CFs, cardiac fibroblasts; CMs + CFs, cocultured cardiomyocytes and cardiac
fibroblasts; MCC950, a potent selective NLRP3 inhibitor